You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

Investigational Drug Information for Mizoribine


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Mizoribine?

Mizoribine is an investigational drug.

There have been 6 clinical trials for Mizoribine. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2022.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Nephritis. The leading clinical trial sponsors are Asahi Kasei Pharma Corporation, Lee's Pharmaceutical Limited, and Chong Kun Dang Pharmaceutical.

There are six hundred and eighteen US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Mizoribine
TitleSponsorPhase
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation RecipientsLee's Pharmaceutical LimitedPhase 4
An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant RecipientsLee's Pharmaceutical LimitedPhase 4
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)Regeneron PharmaceuticalsPhase 3

See all Mizoribine clinical trials

Clinical Trial Summary for Mizoribine

Top disease conditions for Mizoribine
Top clinical trial sponsors for Mizoribine

See all Mizoribine clinical trials

US Patents for Mizoribine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mizoribine ⤷  Sign Up Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA) ⤷  Sign Up
Mizoribine ⤷  Sign Up Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA) ⤷  Sign Up
Mizoribine ⤷  Sign Up Compounds useful for the treatment of metabolic disorders and synthesis of the same North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.